Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Melatonin for disability in multiple sclerosis patients
IRCT2017072520258N55Phase 3Completed
- Sponsor
- Arak University of Medical Sciences
- Start
- Apr 2015
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3 trial of melatonin in multiple sclerosis (MS), sponsored by Arak University of Medical Sciences. Primary endpoint: Change in disability (EDSS). Started Apr 2015; status: completed.
02
Drugs
melatonin
03
Conditions
multiple sclerosis (MS)
Beyond the preview
Go deeper on IRCT2017072520258N55.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on IRCT2017072520258N55.